Hostname: page-component-745bb68f8f-l4dxg Total loading time: 0 Render date: 2025-01-11T07:59:23.213Z Has data issue: false hasContentIssue false
  • English
  • Français

Universal Access to Effective Antibiotics is Essential for Tackling Antibiotic Resistance

Published online by Cambridge University Press:  01 January 2021

Nils Daulaire ,
Abhay Bang ,
Göran Tomson ,
Joan N. Kalyango  and
Otto Cars
Get access Rights & Permissions [Opens in a new window]

Extract

The right to health is enshrined in the constitution of the World Health Organization and numerous other international agreements. Yet today, an estimated 5.7 million people die each year (Table 1) from treatable infectious diseases, most of which are susceptible to existing antimicrobials if they were accessible. These deaths occur predominantly among populations living in poverty in low- and middle-income countries, and they greatly exceed the estimated 700,000 annual deaths worldwide currently attributed to antimicrobial resistance (AMR). Ensuring universal appropriate access to antimicrobials is not only a critical part of realizing the right to health, it is necessary for mobilizing effective collective action against the development and spread of AMR.

Type
JLME Supplement
Information
Journal of Law, Medicine & Ethics , Volume 43 , Issue S3 , Autumn 2015 , pp. 17 - 21
Copyright
Copyright © American Society of Law, Medicine and Ethics 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

World Health Organization, Constitution of the World Health Organization (July 22, 1946).Google Scholar
O'Neill, J., Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations (2014); Centers for Disease Control and Prevention, Antibiotic Resistance Threats in the United States, 2013 (2013); European Center for Disease Control and European Medicines Agency, The Bacterial Challenge: Time to React (2009).Google Scholar
GBD 2013 Mortality and Causes of Death Collaborators, “Global, Regional, and National Age-Sex Specific All-Cause and Cause-Specific Mortality for 240 Causes of Death, 1990–2013: A Systematic Analysis for the Global Burden of Disease Study 2013,” The Lancet 385, no. 9963 (2015): 117–171.Google Scholar
Pandey, M. R. Daulaire, N. Starbuck, E. S. Houston, R. M. McPherson, K., “Reduction in Total Under-Five Mortality in Western Nepal through Community-Based Antimicrobial Treatment of Pneumonia,” The Lancet 338, no. 8773 (1991): 993–997; Bang, A. T. Bang, R. A. Tale, O. Sontakke, P. Solanki, J. Wargantiwar, R. Kelzarkar, P., “Reduction in Pneumonia Mortality and Total Childhood Mortality by Means of Community-Based Intervention Trial in Gadchiroli, India,” The Lancet 336, no. 8709 (1990): 201–206, at 8709; Sazawal, S. Black, R. E., Pneumonia Case Management Trials Group, “Effect of Pneumonia Case Management on Mortality in Neonates, Infants, and Preschool Children: A Meta-analysis of Community-Based Trials,” The Lancet Infectious Diseases 3, no. 9 (2003): 547–555, at 9.CrossRefGoogle Scholar
Tshefu, A. et al., “Oral Amoxicillin Compared with Injectable Procaine Benzylpenicillin Plus Gentamicin for Treatment of Neonates and Young Infants with Fast Breathing When Referral Is Not Possible: A Randomized, Open-Label, Equivalence Trial,” The Lancet 385, no. 9979 (2015): 1758–1766.CrossRefGoogle Scholar
World Health Organization, Handbook: IMCI (Integrated Management of Childhood Illness) (2005).Google Scholar
United Nations Children's Fund, Pneumonia and Diarrhea: Tackling the Deadliest Diseases for the World's Poorest Children (2012).Google Scholar
Kallander, K. Young, M. Qazi, S., “Universal Access to Pneumonia Prevention and Care: A Call for Action,” The Lancet Respiratory Medicine 2, no. 12 (2014): 950–952, at 12.Google Scholar
Freedman, R. M. Ingram, D. L. Gross, I. Ehrenkranz, R. A. Warshaw, J. B. Baltimore, R. S., “A Half Century of Neonatal Sepsis at Yale: 1928 to 1978,” American Journal of Diseases of Children 135, no. 142 (1981): 140–144, at 142.CrossRefGoogle Scholar
Bang, A. T. Bang, R. Baitule, S. B. Reddy, M. H. Deshmukh, M. D., “Effect of Home-Based Neonatal Care and Management of Sepsis on Neonatal Mortality: Field Trial in Rural India,” The Lancet 354, no. 9194 (1999): 1955–1961.CrossRefGoogle Scholar
Nsungwa-Sabiti, J. Peterson, S. Pariyo, G. Ogwal-Okeng, J. Petzold, M. Tomson, G., “Home Based Management of Fever Improves Malaria Treatment Practices in Uganda,” Transaction of Royal Society of Tropical Medicine and Hygiene 101, no. 12 (2007): 1199–1207; Arshad, A. Salam, R. A. Lassi, Z. S. Das, J. K. Naqvi, I. Bhutta, Z. A., “Community Based interventions for the Prevention and Control of Tuberculosis,” Infectious Diseases of Poverty 3 (2014): 27–37.Google Scholar
Rao, K. D. Sundararaman, T. Bhatnagar, A. Gupta, G. Kokho, P. Jain, K., “Which Doctor for Primary Health Care? Quality of Care and Non-physician Clinicians in India,” Social Science & Medicine 84 (2013): 30–34.CrossRefGoogle Scholar
Tun, K. M. Imwong, M. Lwin, K. M. Win, A. A. Hlaing, T. M. Hlaing, T. Lin, K. et al., “Spread of Artemisinin-Resistant Plasmodium Falciparum in Myanmar: A Cross-Sectional Survey of the K13 Molecular Marker,” The Lancet Infectious Disesaes (forthcoming 2015).Google Scholar
Balasegaram, M. Clift, C. Røttingen, J. A., “A Pathway towards an Alternative Business Model for Antibiotic Innovation: A framework, Fund and Institutional Mechanism,” Journal of Law, Medicine & Ethics 43, no. 2, Supp. (2015): Online only.Google Scholar
Okeke, I. N. Laxminarayan, R. Bhutta, Z. A. Duse, A. G. Jenkins, P. O'Brien, T. F. Pablos-Mendez, A. Klugman, K. P., “Antimicrobial Resistance in Developing Countries. Part I: Recent Trends and Current Status,” The Lancet Infectious Diseases 5, no. 8 (2005): 481–493; Feikin, D. R. Dowell, S. F. Nwanyanwu, O. C. Klugman, K. P. Kazembe, P. N. Barat, L. M. Graf, C. et al., “Increased Carriage of Trimethoprim/Sulfamethoxazole-Resistant Streptococcus Pneumoniae in Malawian Children after Treatment for Malaria with Sulfadoxine/Pyrimethamine,” Journal of Infectious Diseases 181, no. 4 (2000): 1501–1545.Google Scholar
Grant, G. B. Campbell, H. Dowell, S. F. Graham, S. M. Klugman, K. P. Mulholland, E. K. Steinhoff, M. Weber, M. W. Qazi, S., World Health Organization Department of Child and Adolescent Health and Development, “Recommendations for Treatment of Childhood Non-severe Pneumonia,” The Lancet 9, no. 3 (2009): 185–196.CrossRefGoogle Scholar
World Health Organization, Revised WHO Classification and Treatment of Childhood Pneumonia at Health Facilities: Implications for Policy and Implementation, WHO Department of Maternal, Child, Newborn and Adolescent Health, Geneva (2014).Google Scholar
Zaidi, A. K. Huskins, W. C. Thaver, D. Bhutta, Z. A. Abbas, Z. Goldmann, D. A., “Hospital-Acquired Neonatal Infections in Developing Countries,” The Lancet 365, no. 9465 (2005): 1175–1188.Google Scholar
Nathan, C. Cars, O., “Antibiotic Resistance – Problems, Progress, and Prospects,” New England Journal of Medicine 371, no. 19 (2014): 1761–1763.CrossRefGoogle Scholar
Tomson, G. Vlad, I., “The Need to Look at Antibiotic Resistance from a Health Systems Perspective,” Upsala Journal of Medical Sciences 119, no. 2 (2014): 117–124.CrossRefGoogle Scholar
Ottersen, O. P. Frenk, J. Horton, R., “The Lancet-University of Oslo Commission on Global Governance for Health, in collaboration with the Harvard Global Institute,” The Lancet 378, no. 9803 (2011): 1612–1613.CrossRefGoogle Scholar